Gonadotropin-releasing hormone (GnRH)-antagonist versus GnRH-agonist in ovarian stimulation of poor responders undergoing IVF

被引:50
作者
Fasouliotis, SJ [1 ]
Laufer, N [1 ]
Sabbagh-Ehrlich, S [1 ]
Lewin, A [1 ]
Hurwitz, A [1 ]
Simon, A [1 ]
机构
[1] Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Obstet & Gynecol, IVF Unit, IL-91120 Jerusalem, Israel
关键词
cetrorelix; GnRH-agonist; GnRH-antagonist; IVF; poor responders;
D O I
10.1023/B:JARG.0000006707.88826.e7
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Purpose: The objective of this study was to compare the efficacy of GnRH-antagonists to GnRH-agonists in ovarian stimulation of poor responders undergoing IVF. Methods: Retrospective analysis of our data revealed that 56 patients underwent treatment with a GnRH-agonist according to the flare-up protocol. Patients failing to achieve an ongoing pregnancy (n = 53) were subsequently treated in the next cycle with a GnRH- antagonist according to the multiple-dose protocol. Main outcome measures included the clinical pregnancy and implantation rates. Results: While ovulation induction characteristics and results did not differ between the two protocols, the number of embryos transferred was significantly higher (P = 0.046) in the GnRH- antagonist than in the GnRH-agonist stimulation protocol (2.5 +/- 1.6 vs. 2.0 +/- 1.4, respectively). The clinical pregnancy and implantation rates per transfer in the GnRH- antagonist group appeared higher than in the GnRH- agonist, but did not differ statistically (26.1 and 10.7 compared with 12.2 and 5.9%, respectively). However, the ongoing pregnancy rate per transfer was statistically significantly higher (P = 0.03) in the GnRH- antagonist than in the GnRH- agonist group (23.9 vs. 7.3%, respectively). Conclusion: Applying GnRH- antagonists to ovarian stimulation protocols may offer new hope for IVF poor responder patients. However, further controlled randomized prospective studies with larger sample sizes are required to establish these results.
引用
收藏
页码:455 / 460
页数:6
相关论文
共 20 条
  • [11] Intracytoplasmic sperm injection as a routine indication in low responder patients
    Moreno, C
    Ruiz, A
    Simón, C
    Pellicer, A
    Remohí, J
    [J]. HUMAN REPRODUCTION, 1998, 13 (08) : 2126 - 2129
  • [13] Gonadotropin-releasing hormone antagonist protocol: a novel method of ovarian stimulation in poor responders
    Nikolettos, N
    Al-Hasani, S
    Felberbaum, R
    Demirel, LC
    Kupker, W
    Montzka, P
    Xia, YX
    Schopper, B
    Sturm, R
    Diedrich, K
    [J]. EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2001, 97 (02): : 202 - 207
  • [14] The use of a GnRH antagonist (Cetrorelix®) in a single dose protocol in IVF-embryo transfer:: a dose finding study of 3 versus 2 mg
    Olivennes, F
    Alvarez, S
    Bouchard, P
    Fanchin, R
    Salat-Baroux, J
    Frydman, R
    [J]. HUMAN REPRODUCTION, 1998, 13 (09) : 2411 - 2414
  • [15] Palermo GD, 1996, FERTIL STERIL, V65, P899
  • [16] PELLICER A, 1987, FERTIL STERIL, V47, P812
  • [17] Improved controlled ovarian hyperstimulation in poor responder in vitro fertilization patients with a microdose follicle-stimulating hormone flare, growth hormone protocol
    Schoolcraft, W
    Schlenker, T
    Gee, M
    Stevens, J
    Wagley, L
    [J]. FERTILITY AND STERILITY, 1997, 67 (01) : 93 - 97
  • [18] SCOTT RT, 1994, FERTIL STERIL, V61, P880
  • [19] Clinical and endocrine effects of a microdose GnRH agonist flare regimen administered to poor responders who are undergoing in vitro fertilization
    Surrey, ES
    Bower, J
    Hill, DM
    Ramsey, J
    Surrey, MW
    [J]. FERTILITY AND STERILITY, 1998, 69 (03) : 419 - 424
  • [20] Yang JH, 1997, J REPROD MED, V42, P663